Bisphosphonates inactivate human EGFRs to exert antitumor actions

Proceedings of the National Academy of Sciences of the United States of America

Volumn 111, Issue 50, 2014, Pages 17989-17994

  Yuen, Tony ^a   Stachnik, Agnes ^a   Iqbal, Jameel ^a   Sgobba, Miriam ^b   Gupta, Yogesh ^a   Lu, Ping ^a   Colaianni, Graziana ^a,c   Ji, Yaoting ^a,d   Zhu, Ling Ling ^a,d   Kim, Se Min ^a   Li, Jianhua ^a   Liu, Peng ^a   Izadmehr, Sudeh ^a   Sangodkar, Jaya ^a   Bailey, Jack ^a   Latif, Yathin ^a   Mujtaba, Shiraz ^a   Epstein, Solomon ^a   Davies, Terry F ^a   Bian, Zhuan ^d   Zallone, Alberta ^c   Aggarwal, Aneel K ^a   Haider, Shozeb ^b   New, Maria I ^a   Sun, Li ^a   Narla, Goutham ^a,e   Zaidi, Mone ^a   more..

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF BARI   (Italy)

^d Wuhan University   (China)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Drug repurposing; Her2 neu; Osteoporosis; Receptor tyrosine kinase; Tyrosine kinase inhibitor

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FARNESYL TRANS TRANSFERASE; ISOPROTEIN; MINODRONIC ACID; NITROGEN; PROTEIN TYROSINE KINASE; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID; ANTINEOPLASTIC AGENT; PROTEIN BINDING; TETRAZOLIUM; THIAZOLE DERIVATIVE; THIAZOLYL BLUE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; BREAST CANCER CELL LINE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL FREE SYSTEM; CELL KILLING; COLON CANCER; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; ENZYME ACTIVATION; ENZYME ASSAY; ENZYME INHIBITION; GENE MUTATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MATHEMATICAL MODEL; PROTEIN DOMAIN; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; ANISOTROPY; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CHEMICAL STRUCTURE; CHEMISTRY; CRYSTALLOGRAPHY; DRUG EFFECTS; FLUORESCENCE; METABOLISM; MOLECULAR DYNAMICS; PROTEIN CONFORMATION; TUMOR CELL LINE; WESTERN BLOTTING;

ANISOTROPY; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CRYSTALLOGRAPHY; DIPHOSPHONATES; FLUORESCENCE; HUMANS; MODELS, MOLECULAR; MOLECULAR DYNAMICS SIMULATION; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; TETRAZOLIUM SALTS; THIAZOLES;

EID: 84919360515     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1421410111     Document Type: Article

References (35)

1. Russell RG (2011) Bisphosphonates: The first 40 years. Bone 49(1):2-19.
2. Wilson C, Holen I, Coleman RE (2012) Seed, soil and secreted hormones: potential interactions of breast cancer cells with their endocrine/paracrine microenvironment and implications for treatment with bisphosphonates. Cancer Treat Rev 38(7):877-889.
3. Coleman R, Gnant M, Morgan G, Clezardin P (2012) Effects of bone-targeted agents on cancer progression and mortality. J Natl Cancer Inst 104(14):1059-1067.
4. Gnant M, et al.; ABCSG-12 Trial Investigators (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 360(7):679-691.
5. Coleman RE, et al.; AZURE Investigators (2011) Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med 365(15):1396-1405.
6. Gnant M, et al. (2011) Long-term follow-up in ABCSG-12: Significantly improved overall survival with adjuvant zoledronic acid in premenopausal patients with endocrine-receptor-positive early breast cancer. Cancer Res 71(24, Suppl):S1-S2.
7. Coleman R, et al. (2013) Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): Final 60-month results. Ann Oncol 24(2):398-405.
8. Pazianas M, Abrahamsen B, Eiken PA, Eastell R, Russell RG (2012) Reduced colon cancer incidence and mortality in postmenopausal women treated with an oral bisphosphonate-Danish National Register Based Cohort Study. Osteoporos Int 23(11):2693-2701.
9. Rennert G, Pinchev M, Rennert HS, Gruber SB (2011) Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 29(9):1146-1150.
10. Sendur MA, et al. (2012) Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use. Med Oncol 29(4):2601-2605.
11. Clézardin P, Massaia M (2010) Nitrogen-containing bisphosphonates and cancer immunotherapy. Curr Pharm Des 16(27):3007-3014.
12. Maniar A, et al. (2010) Human gammadelta T lymphocytes induce robust NK cellmediated antitumor cytotoxicity through CD137 engagement. Blood 116(10):1726-1733.
13. Benzaïd I, et al. (2011) High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo. Cancer Res 71(13):4562-4572.
14. Inoue R, et al. (2005) The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br J Pharmacol 146(5):633-641.
15. Di Salvatore M, et al. (2011) Anti-tumour and anti-angiogenetic effects of zoledronic acid on human non-small-cell lung cancer cell line. Cell Prolif 44(2):139-146.
16. Tang X, et al. (2010) Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1alpha/VEGF signaling pathways in human breast cancer cells. Int J Cancer 126(1):90-103.
17. Stresing V, et al. (2011) Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone 48(2):259-266.
18. Ding L, et al. (2008) Somatic mutations affect key pathways in lung adenocarcinoma. Nature 455(7216):1069-1075.
19. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358(11):1160-1174.
20. Nishino M, et al. (2011) Imaging of lung cancer in the era of molecular medicine. Acad Radiol 18(4):424-436.
21. Shepard HM, Brdlik CM, Schreiber H (2008) Signal integration: A framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest 118(11):3574-3581.
22. Ljuslinder I, et al. (2007) LRIG1 expression in colorectal cancer. Acta Oncol 46(8):1118-1122.
23. Lamb J, et al. (2006) The Connectivity Map: Using gene-expression signatures to connect small molecules, genes, and disease. Science 313(5795):1929-1935.
24. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125(6):1137-1149.
25. Stamos J, Sliwkowski MX, Eigenbrot C (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277(48):46265-46272.
26. Yun CH, et al. (2007) Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11(3):217-227.
27. Park JH, Liu Y, Lemmon MA, Radhakrishnan R (2012) Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochem J 448(3):417-423.
28. Takano T, et al. (2005) Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent nonsmallcell lung cancer. J Clin Oncol 23(28):6829-6837.
29. Mitsudomi T, et al. (2005) Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23(11):2513-2520.
30. Yun CH, et al. (2008) The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci USA 105(6):2070-2075.
31. Rogers MJ (2003) New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des 9(32):2643-2658.
32. Krasinskas AM (2011) EGFR signaling in colorectal carcinoma. Pathol Res Int 2011:932932.
33. Schlessinger J (2002) Ligand-induced, receptor-mediated dimerization and activation of EGF receptor. Cell 110(6):669-672.
34. Stachnik A, et al. (2014) Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer. Proc Natl Acad Sci USA 111:17995-18000.
35. Sangodkar J, et al. (2012) Targeting the FOXO1/KLF6 axis regulates EGFR signaling and treatment response. J Clin Invest 122(7):2637-2651.